PREFER - Why, when and how to assess and use patient preferences in medical product decision-making

Part of EU Open Research Repository
Published December 2, 2021 | Version v1
Presentation Open

PREFER case studies on rheumatoid arthritis

Creators

  • 1. University of Birmingham
  • 2. Uppsala University
  • 3. patient research partner
  • 4. Erasmus University Rotterdam
  • 5. Janssen R&D

Description

In this webinar, insights will be shared on two patient preference studies focusing on treatments for Rheumatoid Arthritis and treatments to prevent Rheumatoid Arthritis. Their design, the results, potential impact and how we worked with patient research partners to develop these studies and the impact of this collaboration.

Rheumatoid arthritis (sometimes called “RA”) is a long term condition that mainly affects the joints and causes pain, swelling, stiffness and often fatigue. RA is fairly common and affects around 1% of the population. In most cases, patients begin having symptoms between 40 to 60 years of age, but it can also begin earlier, or later in life.

Files

PREFER RA webinar final.pdf

Files (4.7 MB)

Name Size Download all
md5:e48fe160e59f86396cc5dba2bad757c2
4.7 MB Preview Download

Additional details

Funding

European Commission
PREFER – Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 115966